MDGL
Madrigal Pharmaceuticals, Inc. NASDAQ Listed Feb 6, 2007$510.04
-0.06%
vs $510.36
Mkt Cap $11.8B
52w Low $342.73
61.5% of range
52w High $615.00
50d MA $514.90
200d MA $508.91
P/E (TTM)
—
EV/EBITDA
—
P/B
19.0x
Debt/Equity
0.6x
ROE
-47.8%
P/FCF
-60.2x
RSI (14)
43.10
ATR (14)
$22.18
Beta
-1.01
50d MA
$514.90
200d MA
$508.91
Avg Volume
440.4K
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Four Tower Bridge · West Conshohocken, PA 19428 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | BMO | -2.71 | -1.99 | +26.6% | 546.88 | -7.6% | -9.8% | -5.2% | +3.1% | +5.3% | +1.3% | — |
| May 6, 2026 | BMO | -3.61 | -3.25 | +10.0% | 502.47 | +5.7% | +7.4% | -0.9% | -4.6% | -2.6% | +2.7% | — |
| Feb 19, 2026 | BMO | 0.04 | -2.57 | -6525.0% | 491.49 | -8.0% | -11.1% | -0.4% | +0.6% | +0.5% | -1.1% | — |
| Nov 4, 2025 | BMO | -2.04 | -5.08 | -149.4% | 412.35 | -1.5% | +7.8% | +7.0% | +2.7% | +0.1% | +1.4% | — |
| Aug 5, 2025 | BMO | -3.48 | -1.90 | +45.4% | 312.11 | +12.1% | +8.6% | -0.2% | +1.2% | +1.0% | +1.1% | — |
| May 1, 2025 | BMO | -3.62 | -3.32 | +8.3% | 333.91 | +4.5% | -1.9% | -3.7% | -2.9% | -3.7% | +1.3% | — |
| Feb 26, 2025 | BMO | -4.32 | -2.71 | +37.3% | 309.49 | +8.2% | +15.0% | -5.7% | +1.6% | -8.1% | +2.5% | — |
| Oct 31, 2024 | BMO | -6.94 | -4.92 | +29.1% | 215.93 | +13.8% | +20.1% | +23.2% | +3.7% | +1.9% | +0.2% | — |
| Aug 7, 2024 | BMO | -7.55 | -7.10 | +6.0% | 266.56 | -6.6% | -12.2% | +4.1% | -2.7% | +2.1% | +0.6% | — |
| May 7, 2024 | BMO | -6.06 | -7.38 | -21.8% | 235.57 | -5.8% | -7.5% | -4.6% | -0.5% | -0.8% | +3.0% | — |
| Feb 28, 2024 | BMO | -5.32 | -5.68 | -6.8% | 239.80 | -0.3% | +6.0% | -7.1% | +6.5% | -2.0% | +0.8% | — |
| Nov 6, 2023 | BMO | -4.78 | -5.34 | -11.7% | 146.89 | -2.4% | +0.3% | +3.2% | -5.7% | -4.9% | +1.8% | — |
| Aug 8, 2023 | BMO | -4.47 | -4.69 | -4.9% | 179.49 | -2.5% | -5.8% | -0.2% | +1.8% | -0.2% | +1.2% | — |
| May 9, 2023 | BMO | -4.98 | -4.23 | +15.1% | 308.87 | -0.8% | -3.0% | -2.5% | -1.4% | +1.7% | -0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 4 | Wolfe Research | Upgrade | Peer Perform → Outperform | $605 | $482.00 | $492.73 | +2.2% | +5.3% | +1.3% | -0.7% | -0.1% | — |
| Jul 27 | Wells Fargo | Initiates | Overweight | $685 | $544.51 | $555.00 | +1.9% | +1.2% | -2.3% | +1.5% | -9.8% | -5.2% |
| Feb 20 | BofA Securities | Maintains | Neutral → Neutral | — | $436.87 | $435.01 | -0.4% | -0.4% | +0.6% | +0.5% | -1.1% | +2.5% |
| Jan 20 | Citizens | Maintains | Market Outperform → Market Outperform | — | $501.68 | $491.94 | -1.9% | +0.7% | -1.6% | +0.2% | -3.5% | +3.9% |
| Dec 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $544.41 | $552.42 | +1.5% | +8.6% | +2.0% | -0.1% | +0.1% | -0.6% |
| Dec 11 | B. Riley Securities | Maintains | Buy → Buy | — | $552.47 | $559.13 | +1.2% | +3.4% | +0.0% | -1.9% | -1.1% | -1.5% |
| Nov 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $542.12 | $542.85 | +0.1% | +1.1% | +7.3% | +0.7% | +1.5% | -0.7% |
| Nov 20 | Oppenheimer | Maintains | Outperform → Outperform | — | $555.60 | $562.71 | +1.3% | -2.4% | +1.1% | +7.3% | +0.7% | +1.5% |
| Nov 19 | Truist | Maintains | Buy → Buy | — | $558.99 | $554.39 | -0.8% | -0.6% | -2.4% | +1.1% | +7.3% | +0.7% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $528.94 | $527.37 | -0.3% | -2.6% | +2.8% | +4.6% | +1.0% | -0.6% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $495.88 | $491.39 | -0.9% | +9.2% | -2.3% | -2.6% | +2.8% | +4.6% |
| Nov 5 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $444.64 | $450.90 | +1.4% | +7.0% | +2.7% | +0.1% | +1.4% | +9.2% |
| Nov 5 | Citizens | Maintains | Market Outperform → Market Outperform | — | $444.64 | $450.90 | +1.4% | +7.0% | +2.7% | +0.1% | +1.4% | +9.2% |
| Nov 3 | BofA Securities | Upgrade | Underperform → Neutral | — | $418.90 | $421.64 | +0.7% | -1.6% | +7.8% | +7.0% | +2.7% | +0.1% |
| Oct 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $437.10 | $444.33 | +1.7% | -0.8% | +2.0% | -0.7% | +0.2% | -2.3% |
| Oct 10 | Oppenheimer | Maintains | Outperform → Outperform | — | $428.30 | $428.71 | +0.1% | +0.3% | -0.4% | +2.2% | -0.8% | +2.0% |
| Sep 29 | B. Riley Securities | Maintains | Buy → Buy | — | $424.23 | $427.85 | +0.9% | +4.4% | +3.5% | -2.1% | +0.1% | -1.5% |
| Sep 12 | Canaccord Genuity | Maintains | Buy → Buy | — | $439.45 | $439.99 | +0.1% | -1.6% | -1.5% | +0.3% | -2.3% | +5.6% |
| Aug 26 | TD Cowen | Maintains | Buy → Buy | — | $412.23 | $412.69 | +0.1% | +3.1% | +0.0% | +2.8% | +0.2% | -0.4% |
| Aug 20 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $379.55 | $380.61 | +0.3% | +3.2% | +3.9% | +1.9% | -0.6% | +3.1% |
| Aug 12 | UBS | Maintains | Buy → Buy | — | $349.50 | $352.48 | +0.9% | +2.7% | +4.0% | -0.6% | -0.4% | +5.8% |
| Aug 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $338.91 | $333.48 | -1.6% | -0.2% | +1.2% | +1.0% | +1.1% | +2.7% |
| May 2 | B. Riley Securities | Maintains | Buy → Buy | — | $327.70 | $329.86 | +0.7% | -3.7% | -2.9% | -3.7% | +1.3% | +0.2% |
| May 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $327.70 | $329.86 | +0.7% | -3.7% | -2.9% | -3.7% | +1.3% | +0.2% |
| May 2 | UBS | Maintains | Buy → Buy | — | $327.70 | $329.86 | +0.7% | -3.7% | -2.9% | -3.7% | +1.3% | +0.2% |
| Apr 24 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $308.79 | $309.17 | +0.1% | +3.6% | +2.1% | +1.4% | +2.9% | -2.0% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $355.88 | $361.38 | +1.5% | -5.7% | +1.6% | -8.1% | +2.5% | +8.1% |
| Feb 27 | Citigroup | Maintains | Buy → Buy | — | $355.88 | $361.38 | +1.5% | -5.7% | +1.6% | -8.1% | +2.5% | +8.1% |
| Jan 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $303.71 | $304.80 | +0.4% | -9.7% | +0.1% | -0.6% | +7.6% | +4.6% |
| Jan 10 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $333.39 | $323.05 | -3.1% | +1.7% | -10.4% | -9.7% | +0.1% | -0.6% |
| Nov 5 | B. Riley Securities | Maintains | Neutral → Neutral | — | $331.32 | $331.00 | -0.1% | +1.9% | +0.2% | +4.9% | -1.2% | -3.1% |
| Nov 1 | UBS | Maintains | Buy → Buy | — | $259.34 | $274.98 | +6.0% | +23.2% | +3.7% | +1.9% | +0.2% | +4.9% |
| Oct 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $203.59 | $204.44 | +0.4% | -0.5% | +0.3% | +3.8% | +3.0% | +0.4% |
| Oct 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $208.89 | $208.20 | -0.3% | -2.5% | -0.5% | +0.3% | +3.8% | +3.0% |
| Aug 8 | Citigroup | Maintains | Buy → Buy | — | $234.08 | $241.18 | +3.0% | +4.1% | -2.7% | +2.1% | +0.6% | -0.1% |
| Aug 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $234.08 | $241.18 | +3.0% | +4.1% | -2.7% | +2.1% | +0.6% | -0.1% |
| Jul 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $279.95 | $281.77 | +0.7% | -2.2% | -1.6% | +3.6% | +2.9% | -0.1% |
| May 10 | B. Riley Securities | Maintains | Neutral → Neutral | — | $206.92 | $206.40 | -0.3% | -0.8% | +3.0% | -0.2% | +0.4% | +2.6% |
| May 8 | Citigroup | Maintains | Buy → Buy | — | $217.96 | $211.52 | -3.0% | -4.6% | -0.5% | -0.8% | +3.0% | -0.2% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $217.96 | $211.52 | -3.0% | -4.6% | -0.5% | -0.8% | +3.0% | -0.2% |
| May 8 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $217.96 | $211.52 | -3.0% | -4.6% | -0.5% | -0.8% | +3.0% | -0.2% |
| Mar 20 | Evercore ISI | Maintains | Outperform → Outperform | — | $265.68 | $267.50 | +0.7% | -2.5% | -1.4% | -2.8% | -0.2% | +0.0% |
| Mar 15 | B. Riley Securities | Upgrade | Sell → Neutral | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | TD Cowen | Maintains | Outperform → Outperform | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | Canaccord Genuity | Maintains | Buy → Buy | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | UBS | Maintains | Buy → Buy | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | Citigroup | Maintains | Buy → Buy | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Mar 15 | JMP Securities | Maintains | Outperform → Outperform | — | $243.57 | $293.90 | +20.7% | +11.0% | +4.8% | -6.2% | -2.5% | -1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 280 | $555.05 | $155K | 209,329 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 1 | $550.72 | $551 | 209,609 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 153 | $550.01 | $84K | 209,610 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 47 | $548.87 | $26K | 209,763 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 680 | $547.70 | $372K | 209,810 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 269 | $547.08 | $147K | 210,490 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 275 | $545.71 | $150K | 210,759 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 545 | $544.71 | $297K | 211,034 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 110 | $543.79 | $60K | 211,579 | +2.07% | +1.24% |
| Jul 20, 2026 | Sibold William JohnDir/Off | President and CEO | Sell | 140 | $542.75 | $76K | 211,689 | +2.07% | +1.24% |
| Jun 1, 2026 | Soergel DavidOff | Chief Medical Officer | Sell | 1,042 | $495.74 | $517K | 10,033 | -5.90% | -4.05% |
| May 18, 2026 | Soergel DavidOff | Chief Medical Officer | Sell | 844 | $515.90 | $435K | 11,075 | -1.99% | +1.36% |
8-K
Madrigal Pharmaceuticals, Inc. -- 8-K Filing
Jul 30
8-K
Madrigal Pharmaceuticals, Inc. -- 8-K Filing
Madrigal Pharmaceuticals reported strong Q1 2026 results for its MASH-focused pipeline, with CEO Bill Sibold signaling positive momentum heading into the year.
May 6
8-K
Madrigal Pharmaceuticals, Inc. -- 8-K Filing
Madrigal Pharmaceuticals achieved $958.4 million in Rezdiffra sales for 2025 with over 36,250 patients and $988.6 million in cash, supporting its robust MASH pipeline development.
Feb 19
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Janus Henderson Group Plc | 2,018,647 | $1.1B | New | Mar 2026 |
| 2 | Rtw Investments, Lp | 1,993,687 | $1.0B | — | Mar 2026 |
| 3 | Avoro Capital Advisors Llc | 1,818,181 | $952M | Added | Mar 2026 |
| 4 | Paulson & Co | 1,392,188 | $729M | New | Mar 2026 |
| 5 | Vanguard Portfolio Management Llc | 841,145 | $440M | New | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 827,144 | $433M | New | Mar 2026 |
| 7 | Fmr Llc | 511,728 | $268M | Added | Mar 2026 |
| 8 | Citadel Advisors Llc | 453,843 | $238M | Added | Mar 2026 |
| 9 | William Blair Investment Management, Llc | 340,519 | $178M | Reduced | Mar 2026 |
| 10 | Morgan Stanley | 300,924 | $175M | Reduced | Dec 2025 |
| 11 | Invesco Ltd. | 329,519 | $172M | Reduced | Mar 2026 |
| 12 | Alkeon Capital Management Llc | 240,000 | $140M | Added | Dec 2025 |
| 13 | Hood River Capital Management Llc | 249,511 | $131M | Added | Mar 2026 |
| 14 | Lord, Abbett & Co. Llc | 242,726 | $127M | Reduced | Mar 2026 |
| 15 | Point72 Asset Management | 225,510 | $118M | Added | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 189,527 | $99M | Reduced | Mar 2026 |
| 17 | Artisan Partners Limited Partnership | 183,540 | $96M | Reduced | Mar 2026 |
| 18 | Northern Trust Corp | 149,214 | $78M | Reduced | Mar 2026 |
| 19 | Bank Of New York Mellon Corp | 135,908 | $71M | Reduced | Mar 2026 |
| 20 | Woodline Partners Lp | 125,899 | $66M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$11.78B
Enterprise Value
$10.81B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
1.10x
P/B
18.99x
P/S
9.18x
P/FCF
-60.22x
EV/EBITDA
—
Shares Out
22.4M
Financials (TTM)
Revenue
$1.28B
Net Income
-$325.1M
EBITDA
-$298.8M
Free Cash Flow
-$190.0M
Op Cash Flow
-$189.6M
EPS Basic
$-12.85
EPS Diluted
$-12.89
EPS Forward
$-4.66
Gross Margin
91.5%
Op Margin
-25.1%
Net Margin
-25.3%
Balance Sheet
Total Assets
$1.26B
Total Liab.
$656.9M
Total Equity
$602.7M
Cash
$983.6M
LT Debt
$346.6M
Book Value/Sh
$26.86
Debt/Equity
0.59x
Current Ratio
4.01
Quick Ratio
3.77
Returns & Growth
ROE
-47.8%
ROA
-22.9%
ROIC
-31.6%
Rev Growth YoY
+432.1%
EPS Growth YoY
+41.3%
Price Returns
2W
-6.3%
1M
-9.8%
3M
+0.0%
6M
+6.8%
12M
+47.5%
Technicals
52W High
$615.00
52W Low
$342.73
50d MA
$514.90
200d MA
$508.91
RSI (14)
43.10
ATR (14)
$22.18
Beta
-1.01
Avg Volume
440K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$705.67
High
$964.00
Low
$527.00
Median
$640.00
Data updated apr 26, 2026 11:39am
· Source: financialmodelingprep.com